Status:
UNKNOWN
Influence of Bilateral Arm Ischemic Postconditioning on Clinical Prognosis and Outcome in Acute Ischemic Stroke Patients
Lead Sponsor:
The First Hospital of Jilin University
Conditions:
Remote Ischemic Postconditioning
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Influence of bilateral arm ischemic postconditioning （BAIPC）on the injury and protective blood markers and the clinical prognosis and outcome in patients with acute ischemic stroke
Detailed Description
In this study, we explore the influence of bilateral arm ischemic postconditioning (BAIPC) to patients with anterior circulation acute ischemic stroke. Patients with anterior circulation acute ischemi...
Eligibility Criteria
Inclusion
- Patients with ischemic cerebral stroke within 72 hours, NIHSS score between 4 to 15 points;
- Age between 18-80 years ,gender not limited;
- freely given informed consent.
Exclusion
- Patients with progressive neurological disease or patients that cannot survive more than 1 year
- Patients suspected intracranial artery dissection, moyamoya disease, any known vascular inflammatory disease, radioactive vascular lesions, fibromuscular dysplasia, sickle cell disease, tumor, reversible cerebral vascular contraction and reversible posterior leukoencephalopathy syndrome
- Patients with Cardioembolism , such as rheumatic mitral or aortic stenosis, artificial heart valve, sick sinus syndrome, left atrial myxoma, left ventricular mural thrombus or valvular vegetations, congestive heart failure, bacterial endocarditis
- Patients with uncontrollable severe hypertension (after drug treatment, systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg) Patients with subclavian artery stenosis 50% or higher or subclavian artery steal blood syndrome and upper limb arterial occlusion
- Patients with serum Aspertate aminotransferase or Alanine transaminase concentration 3 times higher than normal ceiling Patients that Creatinine clearance \< 0.6 ml/s or serum creatinine \>265 umol/l (\> 3.0 mg/dl)
- Patients once with intracranial tumors or brain aneurysm, arteriovenous malformation
- Patients with intracranial bleeding occurred within 90 days (parenchymal hemorrhage, subarachnoid hemorrhage, subdural out/epidural blood), retinal hemorrhage or visceral bleeding occurred within 30 days.
- Patients with severe blood system disease or severe blood coagulation disfunction , platelet \< 100 x 109 / L;
- Patients that received major surgery 30 days before or is expected to wthin 12 months (including femoral artery, heart, the aorta or the carotid surgery);
- Patients whose Target lesion blood vessel had received a stent implantation, angioplasty or other medical treatment, or is expected to above treatments witnin 12 months ;
- Patients with BAIPC contraindications, e.g. severe soft tissue injuries, such as the upper extremity fractures or blood vessels lesions.
Key Trial Info
Start Date :
November 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03335111
Start Date
November 1 2016
End Date
January 1 2019
Last Update
November 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First hospital of Jilin University
Changchun, Jilin, China, 130000